S.R.I.W.

Type

Venture Capital

Location

Liège, Belgium

Total investments

116

Average round size

11M

Portfolio companies

94

Rounds per year

2.58

Lead investments

20

Follow on index

0.19

Exits

9

Stages of investment
Early Stage Venture
Areas of investment
BiotechnologySoftwareInformation TechnologyHealth CareHealth DiagnosticsManufacturingMedical DeviceMedicalPharmaceuticalTherapeutics

Summary

S.R.I.W. is the famous Corporate Investor, which was founded in 1979. The venture was found in Europe in Belgium. The main department of described Corporate Investor is located in the Liu00e8ge.

The overall number of key employees were 7.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the S.R.I.W., startups are often financed by SFPI-FPIM, Vesalius Biocapital Partners, Sambrinvest. The meaningful sponsors for the fund in investment in the same round are Vesalius Biocapital Partners, Sambrinvest, Capricorn Venture Partners. In the next rounds fund is usually obtained by SFPI-FPIM, Sambrinvest, Vesalius Biocapital Partners.

The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this Corporate Investor is 4 percentage points more often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars. This S.R.I.W. works on 21 percentage points less the average amount of lead investments comparing to the other organizations. The increased amount of exits for fund were in 2017. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity.

Among the most successful fund investment fields, there are Information Technology, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Belgium. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Minoryx Therapeutics, iSTAR Medical, Miracor Medical.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesDeep TechAI/Big DataIoTBlockchain/Crypto/Web3 Show 2 more
Stage focus
Seed
Geo focus
Belgium, Wallonia

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
116
Lead investments
20
Exits
9
Rounds per year
2.58
Follow on index
0.19
Investments by industry
  • Health Care (37)
  • Biotechnology (36)
  • Manufacturing (17)
  • Medical (16)
  • Pharmaceutical (15)
  • Show 106 more
Investments by region
  • Belgium (104)
  • United States (5)
  • France (2)
  • Spain (1)
  • Netherlands (2)
  • Show 1 more
Peak activity year
2018
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
22
Avg. valuation at time of investment
48M
Group Appearance index
0.56
Avg. company exit year
14
Avg. multiplicator
8.63
Strategy success index
0.50

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
EsoBiotec 30 Sep 2021 Biotechnology Seed 3M Brabant Wallon, Mont-saint-guibert, Belgium
ExeVir Bio 28 Jul 2020 Biotechnology, Health Care, Life Science, Therapeutics Early Stage Venture 49M East Flanders, Ghent, Belgium

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.